Cholestyramine Alternatives Compared
Cholestyramine | Stelara (ustekinumab) | Entyvio (vedolizumab) |
|
---|
Cholestyramine | Stelara (ustekinumab) | Entyvio (vedolizumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Dumping Syndrome, Crohn's Disease, Pruritus of Partial Biliary Obstruction, High Cholesterol, Hyperlipoproteinemia Type IIa - Elevated LDL, Hyperlipoproteinemia, Hyperlipoproteinemia... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Crohn's Disease
Popular comparisons
|
|||||||||||||||||||||||
More about Cholestyramine | More about Stelara (ustekinumab) | More about Entyvio (vedolizumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Cholestyramine has an average rating of 8.9 out of 10 from a total of 248 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 7% reported a negative effect. |
Stelara has an average rating of 7.7 out of 10 from a total of 250 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 15% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 161 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cholestyramine prices |
View all Stelara prices |
View all Entyvio prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Cholestyramine Light, Prevalite | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
2 hours |
1291.2 hours |
600 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 137 drugs are known to interact with Cholestyramine:
|
A total of 529 drugs are known to interact with Stelara:
|
A total of 159 drugs are known to interact with Entyvio:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
September 25, 2009 |
May 20, 2014 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.